Skip to main content
. 2009 Mar 6;113(21):5074–5082. doi: 10.1182/blood-2009-02-202937

Figure 4.

Figure 4

Analysis of major outcomes shows no benefit of MMF for initial treatment of chronic GVHD. (A) Outcomes according to treatment arm. (B) Hazard ratio estimates and 95% confidence intervals for outcomes among patients in the MMF arm compared with those in the control arm. (A) — represent the MMF group; and ----, control group. (B) Hazard ratio estimates and confidence intervals were derived from Cox regression analysis stratified on the number of involved sites at onset (1 vs > 1) and conditioning regimen (myeloablative vs nonmyeloablative).